Clinical Trial

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT07415980
Lead Sponsor Sun Yat-sen University
Conditions Double Expressor DLBCL
Enrollment 68 participants
Start Date 2026-04-01
Primary Completion 2028-04-01 (estimated)
Study Completion 2031-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-17